HIV感染症：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 19
2 Introduction 21
2.1 Catalyst 21
2.2 Related Reports 22
2.3 Upcoming Related Reports 22
3 Disease Overview 23
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 Pathophysiology 26
3.1.3 Prognosis 26
3.1.4 Quality of Life 27
3.2 Symptoms 27
3.2.1 Primary or Acute Infection 27
3.2.2 Chronic Infection 27
3.2.3 Advanced Infection/AIDS 28
4 Epidemiology 29
4.1 Risk Factors and Comorbidities 29
4.1.1 Condoms decrease HIV transmission by nearly 90% 30
4.1.2 Bodily fluids are the second most common mode of HIV transmission 30
4.1.3 Antiretrovirals reduce perinatal transmission as much as 99% 31
4.1.4 HIV/HCV co-infection complicates treatment options and accelerates liver damage 32
4.1.5 13% of new TB cases are among people with HIV 32
4.2 Global Trends 33
4.2.1 US 34
4.2.2 France 36
4.2.3 Germany 38
4.2.4 Italy 40
4.2.5 Spain 42
4.2.6 UK 45
4.2.7 Japan 46
4.2.8 Brazil 46
4.2.9 India 47
4.2.10 China 47
4.3 Forecast Methodology 49
4.3.1 Sources Used 51
4.4 Forecast Assumptions and Methods 55
4.4.1 Incident Cases 55
4.4.2 Prevalent Cases 59
4.5 Sources Not Used 62
4.6 Epidemiology Forecast 63
4.6.1 Incidence 63
4.6.2 Prevalence 71
4.6.3 Prevalent Cases of HIV Segmented by Comorbidities 80
4.6.4 Antiretroviral Use in Prevalent HIV Cases 83
4.7 Discussion 84
4.8 Limitations of This Analysis 85
4.9 Strengths of Analysis 86
5 Disease Management 87
5.1 Treatment Overview 87
5.2 US 91
5.2.1 Diagnosis 91
5.2.2 Clinical Practice 91
5.3 France 93
5.3.1 Diagnosis 93
5.3.2 Clinical Practice 93
5.4 Germany 95
5.4.1 Diagnosis 95
5.4.2 Clinical Practice 96
5.5 Italy 98
5.5.1 Diagnosis 98
5.5.2 Clinical Practice 98
5.6 Spain 100
5.6.1 Diagnosis 100
5.6.2 Clinical Practice 101
5.7 UK 103
5.7.1 Diagnosis 103
5.7.2 Clinical Practice 104
5.8 Japan 105
5.8.1 Diagnosis 105
5.8.2 Clinical Practice 106
5.9 Brazil 107
5.9.1 Diagnosis 107
5.9.2 Clinical Practice 108
5.10 China 109
5.10.1 Diagnosis 109
5.10.2 Clinical Practice 110
6 Competitive Assessment 112
6.1 Overview 112
6.2 Strategic Competitor Assessment 112
6.3 Product Profiles – Major Brands 115
6.3.1 Atripla (efavirenz/emtricitabine/tenofovir) 115
6.3.2 Complera (emtricitabine/tenofovir/rilpivirine) 122
6.3.3 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) 128
6.3.4 Truvada (tenofovir disoproxil fumarate/emtricitabine) 134
6.3.5 Epzicom (abacavir/lamivudine) 139
6.3.6 Kaletra (lopinavir/ritonavir) 145
6.3.7 Reyataz (atazanavir) 151
6.3.8 Prezista (darunavir) 156
6.3.9 Norvir (ritonavir) 161
6.3.10 Isentress (raltegravir) 166
6.3.11 Entry inhibitors 171
7 Opportunity and Unmet Need 172
7.1 Overview 172
7.1.1 Simplified regimens and dosing frequency 172
7.1.2 Side effects and toxicities 173
7.1.3 Drug resistance 173
7.1.4 Prophylaxis 174
7.1.5 Lack of functional cure 174
7.1.6 Patient awareness 175
7.1.7 Treatment availability 175
7.1.8 Treatment affordability 176
7.2 Unmet Needs Gap Analysis 177
7.3 Opportunities 179
7.3.1 Development of treatments to counter drug resistance 179
7.3.2 Collaborations to develop newer STRs 179
7.3.3 Development of new injectable formulations 179
7.3.4 Development of new prophylactics 180
7.3.5 Development of drugs that use a novel mechanism of action 180
7.3.6 Public-Private Partnerships 180
8 Pipeline Assessment 181
8.1 Overview 181
8.2 Clinical Trial Mapping 183
8.2.1 Clinical Trials by Country 183
8.3 Clinical Trials by Phase and Trial Status 184
8.4 Promising Drugs in Clinical Development 185
8.4.1 Cobicistat 187
8.4.2 Elvitegravir 195
8.4.3 Dolutegravir 201
8.4.4 572-Trii 209
8.4.5 Quad 2 216
8.5 Promising Drugs in Earlier Development 223
9 Current and Future Players 224
9.1 Overview 224
9.2 Trends in Corporate Strategy 227
9.3 Company Profiles 228
9.3.1 Gilead 228
9.3.2 ViiV Healthcare 233
9.3.3 AbbVie (Abbott) 238
9.3.4 Merck 241
9.3.5 Janssen (a Subsidiary of J&J) 245
9.3.6 Bristol-Myers Squibb 249
9.3.7 Japan Tobacco 254
9.3.8 Avexa 257
9.3.9 TaiMed Biologics 259
9.3.10 Tobira Therapeutics 261
10 Market Outlook 263
10.1 Global Markets 263
10.1.1 Forecast 263
10.1.2 Drivers and Barriers – Global Issues 267
10.2 US 270
10.2.1 Forecast 270
10.2.2 Key Events 273
10.2.3 Drivers and Barriers 275
10.3 France 278
10.3.1 Forecast 278
10.3.2 Key Events 281
10.3.3 Drivers and Barriers 282
10.4 Germany 283
10.4.1 Forecast 283
10.4.2 Key Events 287
10.4.3 Drivers and Barriers 287
10.5 Italy 289
10.5.1 Forecast 289
10.5.2 Key Events 293
10.5.3 Drivers and Barriers 294
10.6 Spain 295
10.6.1 Forecast 295
10.6.2 Key Events 299
10.6.3 Drivers and Barriers 300
10.7 UK 302
10.7.1 Forecast 302
10.7.2 Key Events 306
10.7.3 Drivers and Barriers 307
10.8 Japan 310
10.8.1 Forecast 310
10.8.2 Key Events 313
10.8.3 Drivers and Barriers 314
10.9 Brazil 316
10.9.1 Forecast 316
10.9.2 Key Events 319
10.9.3 Drivers and Barriers 320
10.10 China 322
10.10.1 Forecast 322
10.10.2 Key Events 326
10.10.3 Drivers and Barriers 326
11 Appendix 329
11.1 Bibliography 329
11.2 Abbreviations 354
11.3 Methodology 358
11.4 Forecasting Methodology 358
11.4.1 HIV Prevalence 358
11.4.2 Percent Drug-Treated Patients 358
11.4.3 Drugs Included in Each Therapeutic Class 359
11.4.4 Launch and Patent Expiry Dates 361
11.4.5 General Pricing Assumptions 362
11.4.6 Individual Drug Assumptions 363
11.4.7 Generic Erosion 373
11.4.8 Pricing of Pipeline agents 374
11.5 Physicians and Specialists Included in this Study 376
11.5.1 Survey of Prescribing Physicians 377
11.6 About the Authors 378
11.6.1 Authors 378
11.6.2 Epidemiologists 379
11.6.3 Global Head of Healthcare 381
11.7 About GlobalData 382
11.8 Contact Us 382
11.9 Disclaimer 382